BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1664 related articles for article (PubMed ID: 28104840)

  • 1. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
    Davoli T; Uno H; Wooten EC; Elledge SJ
    Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load.
    Jung H; Kim HS; Kim JY; Sun JM; Ahn JS; Ahn MJ; Park K; Esteller M; Lee SH; Choi JK
    Nat Commun; 2019 Sep; 10(1):4278. PubMed ID: 31537801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune evasion in HPV
    William WN; Zhao X; Bianchi JJ; Lin HY; Cheng P; Lee JJ; Carter H; Alexandrov LB; Abraham JP; Spetzler DB; Dubinett SM; Cleveland DW; Cavenee W; Davoli T; Lippman SM
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33952700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
    Li B; Severson E; Pignon JC; Zhao H; Li T; Novak J; Jiang P; Shen H; Aster JC; Rodig S; Signoretti S; Liu JS; Liu XS
    Genome Biol; 2016 Aug; 17(1):174. PubMed ID: 27549193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
    Spranger S
    Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
    Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
    J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8
    Redmond WL; Linch SN
    Hum Vaccin Immunother; 2016 Oct; 12(10):2519-2522. PubMed ID: 27459422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation.
    Buccitelli C; Salgueiro L; Rowald K; Sotillo R; Mardin BR; Korbel JO
    Genome Res; 2017 Apr; 27(4):501-511. PubMed ID: 28320919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.
    Tamborero D; Rubio-Perez C; Muiños F; Sabarinathan R; Piulats JM; Muntasell A; Dienstmann R; Lopez-Bigas N; Gonzalez-Perez A
    Clin Cancer Res; 2018 Aug; 24(15):3717-3728. PubMed ID: 29666300
    [No Abstract]   [Full Text] [Related]  

  • 13. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
    Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.
    Ali OA; Lewin SA; Dranoff G; Mooney DJ
    Cancer Immunol Res; 2016 Feb; 4(2):95-100. PubMed ID: 26669718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
    Roh W; Chen PL; Reuben A; Spencer CN; Prieto PA; Miller JP; Gopalakrishnan V; Wang F; Cooper ZA; Reddy SM; Gumbs C; Little L; Chang Q; Chen WS; Wani K; De Macedo MP; Chen E; Austin-Breneman JL; Jiang H; Roszik J; Tetzlaff MT; Davies MA; Gershenwald JE; Tawbi H; Lazar AJ; Hwu P; Hwu WJ; Diab A; Glitza IC; Patel SP; Woodman SE; Amaria RN; Prieto VG; Hu J; Sharma P; Allison JP; Chin L; Zhang J; Wargo JA; Futreal PA
    Sci Transl Med; 2017 Mar; 9(379):. PubMed ID: 28251903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Immunology of Melanoma.
    Ko JS
    Clin Lab Med; 2017 Sep; 37(3):449-471. PubMed ID: 28802495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
    Khong HT; Restifo NP
    Nat Immunol; 2002 Nov; 3(11):999-1005. PubMed ID: 12407407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint combinations from mouse to man.
    Ai M; Curran MA
    Cancer Immunol Immunother; 2015 Jul; 64(7):885-92. PubMed ID: 25555570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.